Today: 3 May 2026
Browse Category

NYSE:LLY 20 July 2025 - 26 September 2025

Wall Street Rebounds: PCE In‑Line, Tariff Shock, and Fed‑Cut Bets — What It All Means (Sept. 26, 2025)

Wall Street Rebounds: PCE In‑Line, Tariff Shock, and Fed‑Cut Bets — What It All Means (Sept. 26, 2025)

U.S. inflation matched forecasts in August, with PCE up 0.3% from July and 2.7% year-on-year. Stocks rebounded, the S&P 500 and Dow rising about 0.5% by early afternoon. The White House announced new tariffs on drug imports, trucks, and furniture, effective Oct. 1. Treasury yields slipped, with the 10-year near 4.18% after the data release.
26 September 2025
·······
Science Shockers: AI-Created Viruses, “Water Worlds” Debunked & More (Sept 19–20, 2025)

Science Shockers: AI-Created Viruses, “Water Worlds” Debunked & More (Sept 19–20, 2025)

Researchers used AI to design the first viruses from scratch, creating bacteriophages that killed drug-resistant bacteria. Scientists solved why smoking affects ulcerative colitis and Crohn’s disease differently, linking it to mouth bacteria. New Alzheimer’s drugs modestly slowed disease in early stages. Wildfire smoke could kill 70,000 Americans annually by 2050, Stanford researchers warned.
20 September 2025
·····
Eli Lilly’s Weight-Loss Pill Sheds Pounds Fast—But Hits a Plateau: What New Trial Results Mean for the Obesity Drug Race

Eli Lilly’s Weight-Loss Pill Sheds Pounds Fast—But Hits a Plateau: What New Trial Results Mean for the Obesity Drug Race

Eli Lilly’s oral weight-loss drug orforglipron led to about 12% average body weight loss over 72 weeks in a large trial, but results plateaued after a year. The pill’s effect was less than leading injectables like Wegovy and Zepbound. Side effects were mostly mild gastrointestinal issues; no serious liver or thyroid problems were reported. About 10% of patients on the highest dose dropped out due to side effects.
17 September 2025
Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Eli Lilly will invest $5 billion to build a 200,000-square-foot drug manufacturing plant in Goochland County, Virginia, creating 650 permanent jobs and 1,800 construction jobs. The facility will produce active pharmaceutical ingredients for cancer and autoimmune treatments. The project is part of Lilly’s $27 billion U.S. expansion plan. Virginia approved over $10 million in incentives to secure the site.
16 September 2025
·······
Game-Changing AI Breakthroughs, Big Tech Surprises & Global AI Showdowns (Sept 9–10, 2025)

Game-Changing AI Breakthroughs, Big Tech Surprises & Global AI Showdowns (Sept 9–10, 2025)

Researchers at Stony Brook University unveiled an AI tool that detected signs of consciousness in coma patients up to eight days before standard exams. The system analyzed subtle facial muscle movements invisible to doctors. In a study of 37 patients, the AI identified awareness earlier than bedside neurological tests. Up to 25% of patients labeled “unresponsive” may actually be conscious, researchers said.
10 September 2025
·····
Game-Changing Vaccines, Breakthrough Drugs, and a CDC Shakeup: Biotech & Health News Roundup

Game-Changing Vaccines, Breakthrough Drugs, and a CDC Shakeup: Biotech & Health News Roundup

The U.S. administration fired CDC Director Dr. Susan Monarez after she resisted Health Secretary Robert F. Kennedy Jr.’s directives; four senior CDC officials resigned in protest, citing risks to young Americans and pregnant women. U.S. regulators approved updated COVID-19 vaccines for fall, but limited routine access to adults 65+ and high-risk groups, excluding healthy under-65s.
28 August 2025
····
Obesity Pill Breakthrough, Gene Therapy Triumph & Billion-Dollar Psychedelic Bet – Global Biotech & Health Highlights (Aug 26–27, 2025)

Obesity Pill Breakthrough, Gene Therapy Triumph & Billion-Dollar Psychedelic Bet – Global Biotech & Health Highlights (Aug 26–27, 2025)

Eli Lilly’s oral weight-loss drug orforglipron cut body weight by up to 10.5% in a Phase 3 trial for obese diabetics, with all doses meeting primary endpoints over 72 weeks. The FDA granted full approval to Precigen’s Papzimeos, the first gene therapy for adult recurrent respiratory papillomatosis. AbbVie agreed to acquire a psychedelic-based depression drug from Gilgamesh Pharmaceuticals in a deal worth up to $1.2 billion.
27 August 2025
·····
Breakthrough Drugs, Big Deals & Public Health Alerts – Biotech and Health News Roundup (Aug 22–23, 2025)

Breakthrough Drugs, Big Deals & Public Health Alerts – Biotech and Health News Roundup (Aug 22–23, 2025)

The FDA approved Ionis Pharmaceuticals’ Dawnzera as the first RNA-targeted therapy to prevent hereditary angioedema attacks, priced at about $57,462 per dose. AbbVie’s Rinvoq met key endpoints in a second Phase 3 alopecia areata trial, while Scholar Rock’s apitegromab showed significant motor gains in spinal muscular atrophy. Gilead’s Kite Pharma will acquire Interius BioTherapeutics for $350 million.
23 August 2025
·······
Tariff Tsunami, Tech Tumble & Peace Talk Buzz – Global Business Roundup (Aug 19–20, 2025)

Tariff Tsunami, Tech Tumble & Peace Talk Buzz – Global Business Roundup (Aug 19–20, 2025)

Nvidia shares fell sharply on August 19, 2025, as a tech selloff pulled the Nasdaq down 1.5%. President Trump met Ukraine’s president and pledged U.S. support for Ukraine’s security in any peace deal. The U.S. Commerce Department expanded 232 tariffs to 407 new categories, affecting over $200 billion in imports. New Zealand’s central bank cut rates to 3.00%, sending the kiwi dollar to $0.584.
20 August 2025
········
Miracle Drugs, Mega Mergers & Outbreak Alerts – Biotech & Health News Roundup (Aug 15–16, 2025)

Miracle Drugs, Mega Mergers & Outbreak Alerts – Biotech & Health News Roundup (Aug 15–16, 2025)

Wegovy became the first GLP-1 therapy approved by the FDA for MASH, affecting about 5% of U.S. adults. Tonix’s Tonmya was cleared for fibromyalgia, the first new therapy in 15 years. Pfizer’s inclacumab failed a key sickle cell trial, and Oxbryta was withdrawn. BioNTech agreed to acquire CureVac in a $1.25 billion all-stock deal.
16 August 2025
··········
AI Stock Frenzy: Big Tech Bets, Billion-Dollar Deals & Market Shifts (Aug 15–16, 2025)

AI Stock Frenzy: Big Tech Bets, Billion-Dollar Deals & Market Shifts (Aug 15–16, 2025)

Bridgewater more than doubled its Nvidia stake in Q2 2025, while Tiger Global bought millions more Amazon shares and raised bets on Alphabet, Nvidia, Microsoft, and Meta. On August 14, Oracle and Google Cloud announced a partnership to offer Gemini AI models via Oracle Cloud. Insiders said OpenAI is in talks to sell $6 billion in shares at a $500 billion valuation. Tesla shelved its Dojo AI supercomputer and will rely on Nvidia GPUs.
16 August 2025
··········
Global Business Pulse: Markets Juggle Tariffs, Rate Cuts & Mega-Deals (Aug 7–8, 2025)

Global Business Pulse: Markets Juggle Tariffs, Rate Cuts & Mega-Deals (Aug 7–8, 2025)

The United States imposed 100% tariffs on imported chips and electronics Aug. 7, sending Apple shares up 3%. Dow Jones fell 0.5%, S&P 500 slipped 0.1%, and Nasdaq hit a record, while Eli Lilly dropped 14% on weak drug data. The Bank of England cut rates for a fourth time, lifting the pound 0.7%. Paramount Global and Skydance completed an $8.4 billion merger.
8 August 2025
········
From Foldable Phones to Moon Missions: The Biggest Tech News Roundup (July 29–30, 2025)

From Foldable Phones to Moon Missions: The Biggest Tech News Roundup (July 29–30, 2025)

Samsung unveiled the Galaxy Z Fold7 at $1,999 and the Flip7 FE at $899, with the Fold7 26% thinner and 10% lighter than last year’s model. Opera filed an antitrust complaint in Brazil against Microsoft over Edge’s default status. Sony sued Tencent, alleging Light of Motiram copied Horizon Zero Dawn. Figma raised its IPO price range, targeting an $18.8 billion valuation.
30 July 2025
·············
Blast-Off Breakthroughs: Fusion Lasers, Space Feats & Tech Triumphs in Weekend Roundup (July 19–20, 2025)

Blast-Off Breakthroughs: Fusion Lasers, Space Feats & Tech Triumphs in Weekend Roundup (July 19–20, 2025)

SpaceX launched 24 Starlink satellites from California on July 18, bringing the active constellation to nearly 8,000. Raytheon delivered OCX GPS control software to the U.S. Space Force. Senate appropriators voted to restore funding for NASA Earth science and exploration missions in the 2026 budget. China unveiled a fusion laser facility in Mianyang, about 50% larger than the U.S. National Ignition Facility.
20 July 2025
·····
1 … 10 11 12

Stock Market Today

  • Euronext Shares Up 20% in Three Months, Slightly Undervalued at €142.9
    May 3, 2026, 2:16 AM EDT. Euronext (ENXTPA:ENX) shares rose 20.49% over the past three months, closing at €142.9. Despite a modest recent pullback, the stock trades slightly below analysts' average target price of €147.56, suggesting a 3.2% undervaluation based on refreshed growth and profitability forecasts. The discounted cash flow (DCF) model estimates an even higher fair value of €155.94 per share, hinting at potential upside. Key risks include possible volatility reduction and acquisition integration impacting margins. Investors should analyze earnings and revenue assumptions underlying the current valuation narrative before acting.

Latest article

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 03.05.2026

3 May 2026
Rivian shares fell 8.4% to $15.02 after first-quarter results beat expectations, as investors focused on cash burn and profitability concerns. Trading volume jumped 78% above average. The company plans to ramp up R2 SUV production in Georgia to 300,000 units annually. Tesla and Lucid Group shares both rose more than 2%.
Vertiv Stock Tests AI Data-Center Rally as VRT Shares Hit Fresh Highs

Vertiv Stock Tests AI Data-Center Rally as VRT Shares Hit Fresh Highs

3 May 2026
Vertiv shares hit a 52-week high Friday before closing at $328.31, following a 30% jump in Q1 net sales to $2.65 billion. The company raised its 2026 outlook and recently acquired Strategic Thermal Labs, expanding its liquid cooling portfolio. Investors await further details at Vertiv’s May 19-20 conference in South Carolina.
AT&T Inc. Raises $6 Billion as 5G and Fiber Bet Enters a Debt Test

AT&T Inc. Raises $6 Billion as 5G and Fiber Bet Enters a Debt Test

3 May 2026
AT&T closed a $6 billion sale of long-dated notes on April 30, with maturities ranging from 2033 to 2066, according to an SEC filing. The company reported first-quarter free cash flow of $2.5 billion, down from $3.1 billion a year earlier, citing higher capital investment. AT&T is preparing to close a $23 billion purchase of EchoStar spectrum licenses. CFO Pascal Desroches said net debt to adjusted EBITDA rose to 2.71 times.
Go toTop